Sunvozertinib is an oral, irreversible EGFR tyrosine kinase inhibitor (TKI) primarily used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (EGFRexxon20ins).
Its efficacy and effects mainly include the following aspects:
1、 Core efficacy
1. Targeting EGFR Rexon20ins mutation
Shuvotinib selectively inhibits EGFR exon 20 insertion mutations.
This mutation is a rare EGFR mutation, and the efficacy of traditional EGFR-TKI is limited.
Shuvotinib has high inhibitory activity against such mutations.
2. Inhibit tumor growth
Inhibiting tumor cell proliferation by blocking the EGFR signaling pathway.
Can induce apoptosis of tumor cells.
It has anti-tumor effects on NSCLC carrying EGFRexin20ins.
3. Clinical efficacy
Used for locally advanced or metastatic NSCLC patients who have undergone platinum based chemotherapy in the past.
Can improve the objective response rate (ORR).
Extend progression free survival (PFS).
Improve the quality of life for patients.
2、 Function characteristics
1. High selectivity
The selectivity for EGFR Rexon20ins mutation is higher than that of wild-type EGFR.
May reduce some adverse reactions associated with wild-type EGFR inhibition.
2. Irreversible inhibition
Irreversible binding with EGFR, lasting for a long time.
Helps to more persistently inhibit tumor signaling pathways.
3. Oral administration
Convenient for patients to take.
No need for intravenous infusion.
4. Potential to penetrate the blood-brain barrier
Some studies suggest that it may have a certain effect on brain metastasis.
The specific therapeutic effect needs further clinical verification.
3、 Applicable population
NSCLC patients confirmed to have EGFR Rexon20ins mutations through testing.
Patients who have progressed after receiving platinum based chemotherapy in the past.
The specific medication needs to be determined by the doctor based on the results of genetic testing and the condition.
4、 Common adverse reactions
Diarrhea, rash, stomatitis, nausea, decreased appetite, abnormal liver function.
Most adverse reactions are mild to moderate and can be treated accordingly. In severe cases, dosage adjustment or discontinuation of medication may be necessary.
